Solanezumab Does Not Slow Cognitive Decline in Preclinical Alzheimer Disease
Mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab, placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.